Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 2:02 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 16,127 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Disorders Clear all
Completed Not applicable Interventional Results available

Addressing Disparities in Lupus Care Through an Integrated Care Management Program

NCT03915652
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Rheum iCMP
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Nov 3, 2026, 2:02 AM EST
Completed Phase 2 Interventional Results available

A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer

NCT00370552
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg, Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg, Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Burbank, California • La Verne, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Nov 3, 2026, 2:02 AM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03412747
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Plaque Psoriasis
Interventions
Bimekizumab, Adalimumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
478 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
23
States / cities
Glendale, Arizona • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Nov 3, 2026, 2:02 AM EST
Terminated Phase 2 Interventional Results available

Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis

NCT00995449
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
KB003, Placebo Comparator
Biological · Other
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
11
States / cities
Stanford, California • Westlake Village, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Nov 3, 2026, 2:02 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Clinical vs. Anecdotal Evidence - Pediatric Atopic Dermatitis

NCT03559075
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
480 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 18, 2022 · Synced Nov 3, 2026, 2:02 AM EST
Recruiting Phase 2 Interventional

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

NCT07409181
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
BI 3000202, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 74 Years
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
30
States / cities
Beverly Hills, California • La Palma, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2026 · Synced Nov 3, 2026, 2:02 AM EST
Terminated Not applicable Interventional

High Dose Rate Intracavitary Brachytherapy as the Sole Method of Radiation Therapy for Breast Carcinoma

NCT00165581
View directory record Official record
Conditions
Breast Cancer
Interventions
High Dose Intracavitary Brachytherapy
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
45 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 21, 2007 · Synced Nov 3, 2026, 2:02 AM EST
Recruiting Not applicable Interventional Accepts healthy volunteers

Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible Participants

NCT05978128
View directory record Official record
Conditions
Breast Carcinoma, Lung Carcinoma
Interventions
Health Education, Health Promotion and Education, Patient Navigation, Survey Administration
Behavioral · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
40 Years to 80 Years
Enrollment
800 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Nov 3, 2026, 2:02 AM EST
Completed Phase 1 Interventional Results available

Topical Sirolimus for the Treatment of Pachyonychia Congenita (PC)

NCT02152007
View directory record Official record
Conditions
Pachyonychia Congenita
Interventions
1% sirolimus cream (TD201 1%)
Drug
Lead sponsor
TransDerm, Inc.
Industry
Eligibility
16 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Nov 3, 2026, 2:02 AM EST
Recruiting Not applicable Interventional

Survivors Uniting for Remote Guided Exercise

NCT07290309
View directory record Official record
Conditions
Cancer, Cancer (Colon Cancer, Breast Cancer, Lymphoma, Chronic Lymphoma Leukemia, Multiple Myeloma), Physical Activity, Physical Activity Behavior, Cancer (With or Without Metastasis), Cancer - Chronic Lymphocytic Leukemia, Cancer - Ovarian
Interventions
Virtually Supervised Exercise Sessions, Asynchronous Group
Behavioral
Lead sponsor
Colorado State University
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Nov 3, 2026, 2:02 AM EST
Completed No phase listed Observational

Urinary Biomarkers of the Progression of Alport Kidney Disease

NCT01705132
View directory record Official record
Conditions
Alport Syndrome
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
5 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Nov 3, 2026, 2:02 AM EST
Withdrawn Phase 2 Interventional

Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery

NCT00855114
View directory record Official record
Conditions
Breast Cancer
Interventions
everolimus, therapeutic conventional surgery
Drug · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Nov 3, 2026, 2:02 AM EST
Terminated Phase 1 Interventional

FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

NCT05395052
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
Interventions
FT536, Cyclophosphamide, Fludarabine, IL-2, Avelumab, Pembrolizumab, Nivolumab, Atezolizumab, Trastuzumab, Cetuximab, Amivantamab
Drug · Combination Product
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Scottsdale, Arizona • Los Angeles, California • Hackensack, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Nov 3, 2026, 2:02 AM EST
Terminated Phase 1 Interventional

Efficacy Study of Trichuris Suis Ova to Treat Chronic Plaque Psoriasis

NCT01948271
View directory record Official record
Conditions
Psoriasis
Interventions
Trichuris Suis Ova
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 15, 2016 · Synced Nov 3, 2026, 2:02 AM EST
Completed Phase 2 Interventional

Study Evaluating The Efficacy And Safety Of SBI-087 In Seropositive Subjects With Active Rheumatoid Arthritis

NCT01008852
View directory record Official record
Conditions
Active Rheumatoid Arthritis
Interventions
SBI-087, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
20
States / cities
Paradise Valley, Arizona • Palm Desert, California • Santa Monica, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Nov 3, 2026, 2:02 AM EST
Completed Phase 2 Interventional Results available

Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease

NCT03095352
View directory record Official record
Conditions
Breast Cancer, Chest Wall Disease
Interventions
Pembrolizumab, Carboplatin, Trastuzumab
Biological · Drug
Lead sponsor
Laura Huppert, MD, BA
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
7
States / cities
San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Nov 3, 2026, 2:02 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Molecular Analysis of Breast Cancer

NCT00569049
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Non-invasive Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Interventions
breast tissue, lymph node tissue or blood
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
788 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2011
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Nov 3, 2026, 2:02 AM EST
Withdrawn Not applicable Interventional

Clinical Evaluation of the SNaP Wound Care System

NCT01113658
View directory record Official record
Conditions
Acute and Chronic Wounds, Pressure Ulcers, Trauma Wounds, Diabetic Foot Ulcers, Venous Stasis Ulcers
Interventions
SNaP Wound Care System
Device
Lead sponsor
3M
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Daly City, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Nov 3, 2026, 2:02 AM EST
Withdrawn Phase 1 Interventional

Spironolactone for the Treatment of Melasma

NCT03953209
View directory record Official record
Conditions
Melasma
Interventions
Spironolactone 50Mg Tablet, Spironolactone 100Mg Tablet, Spironolactone 200Mg
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 4, 2024 · Synced Nov 3, 2026, 2:02 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)

NCT04152499
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Small-Cell Lung Cancer, Endometrial Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Cervical Cancer
Interventions
SKB264
Drug
Lead sponsor
Klus Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
10
States / cities
Glendale, California • Los Angeles, California • Sarasota, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Nov 3, 2026, 2:02 AM EST
Completed Early Phase 1 Interventional

Keratinocyte Growth Factor- Hair Serum for the Prevention of Chemotherapy Induced Alopecia

NCT04554732
View directory record Official record
Conditions
Alopecia, Chemotherapy-Induced Change, Hair Loss, Alopecia Drugs
Interventions
Keratinocyte growth factor
Drug
Lead sponsor
University of Arizona
Other
Eligibility
21 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 16, 2022 · Synced Nov 3, 2026, 2:02 AM EST
Not listed Phase 3 Interventional

A Study of Valacyclovir as Treatment for Genital Herpes Simplex Virus in HIV-Infected Patients

NCT00005663
View directory record Official record
Conditions
Herpes Simplex, HIV Infections, Herpes Genitalis
Interventions
Valacyclovir hydrochloride
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
20
States / cities
Berkeley, California • Beverly Hills, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 2:02 AM EST
Terminated Phase 1 Interventional

Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy

NCT00629187
View directory record Official record
Conditions
Central Nervous System Neoplasms, Neoplasm Metastasis
Interventions
Temozolomide
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2012 · Synced Nov 3, 2026, 2:02 AM EST
Completed Not applicable Interventional Results available

Developing Strategies for Effective Debridement in Patients for Venous Leg Ulcers

NCT03796793
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
Wound Edge Debridement, Standard of Care Treatment
Procedure · Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Nov 3, 2026, 2:02 AM EST